"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 6 | 7 |
| 1997 | 4 | 11 | 15 |
| 1998 | 2 | 6 | 8 |
| 1999 | 4 | 4 | 8 |
| 2000 | 4 | 8 | 12 |
| 2001 | 3 | 8 | 11 |
| 2002 | 6 | 15 | 21 |
| 2003 | 6 | 15 | 21 |
| 2004 | 5 | 10 | 15 |
| 2005 | 12 | 10 | 22 |
| 2006 | 10 | 7 | 17 |
| 2007 | 11 | 9 | 20 |
| 2008 | 15 | 15 | 30 |
| 2009 | 21 | 7 | 28 |
| 2010 | 17 | 7 | 24 |
| 2011 | 17 | 15 | 32 |
| 2012 | 7 | 11 | 18 |
| 2013 | 13 | 10 | 23 |
| 2014 | 17 | 8 | 25 |
| 2015 | 17 | 12 | 29 |
| 2016 | 21 | 13 | 34 |
| 2017 | 28 | 12 | 40 |
| 2018 | 36 | 8 | 44 |
| 2019 | 20 | 12 | 32 |
| 2020 | 15 | 19 | 34 |
| 2021 | 20 | 18 | 38 |
| 2022 | 4 | 23 | 27 |
| 2023 | 8 | 17 | 25 |
| 2024 | 10 | 9 | 19 |
| 2025 | 16 | 8 | 24 |
| 2026 | 8 | 2 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies. Sci Adv. 2026 Oct 02; 12(40):eaej5440.
-
Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG. Clin Cancer Res. 2026 Oct 01; 32(19):4307-4318.
-
Peripheral human mAb therapy yields modulation of neuroinflammation and long-term functional recovery from lyssavirus infection. Emerg Microbes Infect. 2026 Dec; 15(1):2736987.
-
ACE2-like Catalytic Activity in Anti-SARS-CoV-2 Spike Protein Monoclonal Antibodies. Pathogens. 2026 Sep 04; 15(9).
-
Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial. JAMA Pediatr. 2026 Sep 01; 180(9):951-960.
-
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis. ESMO Open. 2026 Jul; 11(7):108248.
-
Intralesional secukinumab for localized, recalcitrant hidradenitis suppurativa: a case series of rapid symptom relief. J Dermatolog Treat. 2026 Dec; 37(1):2660529.
-
Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits with Severe Acute Kidney Injury Successfully Managed by Clone-Directed Therapy: A Case Report. Nephron. 2026; 150(9):599-607.
-
Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge. J Clin Invest. 2026 May 15; 136(10).
-
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.